27
total announcements
540596.BO · 15 min delayed
Eris Lifesciences Ltd
Eris Lifesciences Ltd has submitted a Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026, confirming the acceptance or rejection of securities received for dematerialisation and listing on stock exchanges.
Eris Lifesciences Ltd
Eris Lifesciences Ltd announced the resignation of Mr. Krishnakumar Vaidyanathan, Executive Director and Chief Operating Officer (COO), effective September 30, 2026, to pursue professional opportunities outside the company.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has announced the closure of its trading window for all Designated Persons and their immediate relatives from October 01, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has submitted the Scrutinizer's consolidated report on remote e-voting and e-voting conducted during the 20th Annual General Meeting held on September 25, 2026.
Eris Lifesciences Ltd
Eris Lifesciences Ltd held its 20th AGM on September 25, 2026, through video conferencing, where the company received and adopted its audited standalone and consolidated financial statements for the year ended March 31, 2026. The meeting also approved the re-appointment of Mr. Sujesh Vasudevan as an independent director and ratified the remuneration of cost auditors for the year ending March 31, 2027.
Eris Lifesciences Ltd
Eris Lifesciences Ltd held its 29th Annual General Meeting on September 25, 2026, through video conferencing, where the company transacted four business items, including the adoption of audited financial statements, appointment of a director, ratification of cost auditors, and re-appointment of an independent director.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has made an allotment of 1,55,264 equity shares under the ESOP-2021 scheme, increasing the company's paid-up share capital from ₹13,85,83,305 to ₹13,87,38,569.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has published a newspaper advertisement regarding the Notice of Twentieth Annual General Meeting and remote E-voting of the Company in Financial Express (English and Gujarati) on 03 September 2026.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has published a newspaper advertisement regarding its 20th Annual General Meeting to be held on September 25, 2026, through video conferencing.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has released its Business Responsibility and Sustainability Report for FY 2025-26, as required by SEBI regulations.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has released its annual report for FY 2025-26, showcasing an 8% YoY growth in revenue and 73% YoY growth in PAT. The company has strengthened its position in the Indian insulin market, with a market share of 25% in RHI Cartridges and 16% in RHI + Glargine. Eris has also achieved a market rank of #1 by sale volume and #2 by sale value in the flagship injectable product Semaglutide.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has scheduled its 20th Annual General Meeting (AGM) on September 25, 2026, through video conferencing. The meeting will consider the audited standalone financial statements for the financial year ended March 31, 2026, and the re-appointment of a director and an independent director.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has announced the re-appointment of Mr. Sujesh Vasudevan as Independent Director of the Company for a period of 5 years from July 25, 2027 to July 24, 2032, and the convening of the 20th Annual General Meeting on September 25, 2026.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has announced an analyst/institutional investor meeting with HBM Partners AG on August 27, 2026, to discuss publicly available documents.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has announced an analyst/institutional investor meeting on August 17, 2026, where the management will discuss publicly available documents and no unpublished price-sensitive information will be disclosed.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has informed the exchanges about an upcoming investor conference, where the company's management will interact with investors and discuss publicly available documents. The meeting is scheduled for August 14, 2026, and will be held virtually.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has drawn down a working capital term loan of ₹64,40,00,000 from Axis Bank Limited to meet other short-term liabilities. The aggregate debt level of the company remains unchanged.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has made available the transcript of its analyst and investor call following the announcement of its financial results for the quarter ended June 30, 2026, on its website.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has announced an analyst/institutional investor meeting on August 4, 2026, where the management will discuss publicly available documents and no unpublished price-sensitive information will be shared.
Eris Lifesciences Ltd
Eris Lifesciences Ltd has informed about the allotment of 4,816 equity shares at a premium of Rs. 450.04 per share under the ESOP-2017 Scheme, increasing the paid-up share capital from Rs. 13,85,78,489 to Rs. 13,85,83,305.